AstraZeneca PLC (AZN)vsNyxoah (NYXH)
AZN
AstraZeneca PLC
$169.64
-0.99%
HEALTHCARE · Cap: $263.09B
NYXH
Nyxoah
$1.40
-0.71%
HEALTHCARE · Cap: $143.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 400252% more annual revenue ($61.37B vs $15.33M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NYXH
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$169.64
$27.29 discount
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Revenue surging 498.9% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : NYXH
The strongest argument for NYXH centers on Price/Book, Revenue Growth. Revenue growth of 498.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH carries more volatility with a beta of 0.96 — expect wider price swings.
NYXH is growing revenue faster at 498.9% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 27/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is an innovative medical technology firm dedicated to advancing treatment options for obstructive sleep apnea (OSA) through its proprietary Genio system, which employs minimally invasive hypoglossal nerve stimulation. The company is committed to clinical validation and extensive research to enhance patient outcomes and quality of life for individuals affected by OSA. By prioritizing innovation in the sleep medicine domain and fostering strategic partnerships, Nyxoah is strategically positioned to leverage the growing demand for effective OSA treatments, indicating strong prospects for long-term growth within the healthcare industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?